Autolus Therapeutics Reports Q2 2025 Financial Results

Autolus Therapeutics ( (AUTL) ) has released its Q2 earnings. Here is a breakdown of the information Autolus Therapeutics presented to its investors.

Autolus Therapeutics plc, a biopharmaceutical company, focuses on developing next-generation T cell therapies for cancer and autoimmune diseases, leveraging proprietary T cell programming technologies.

In its latest earnings report, Autolus Therapeutics announced a net product revenue of $20.9 million for the second quarter of 2025, driven by the early launch performance of AUCATZYL® in the U.S. The company also highlighted recent conditional marketing authorizations in the U.K. and EU, alongside progress in clinical trials for other potential indications.

Key financial metrics revealed a net loss of $47.9 million for the quarter, an improvement from the previous year’s $58.3 million loss. The company is actively expanding its market presence with 46 centers activated in the U.S. and is working on securing market access in the U.K. and EU. Autolus is also advancing its clinical pipeline, with plans to initiate trials in lupus nephritis and multiple sclerosis by year-end.

Autolus presented promising data from its FELIX trial, showing potential long-term remission in r/r B-ALL patients, and is progressing with trials in autoimmune diseases such as systemic lupus erythematosus. The company’s strategic focus remains on expanding its product reach and advancing its clinical programs.

Looking ahead, Autolus is well-capitalized to continue its commercialization efforts and clinical developments, with management optimistic about the growth potential of its pipeline and market expansion strategies.